Eli Lilly has returned to Nimbus Therapeutics for another metabolic collaboration, this time focused on the red-hot R&D space ...

Nimbus and Eli Lilly collaborate to develop an oral treatment for obesity, leveraging computational chemistry and structure-based drug design. Nimbus Therapeutics and Eli Lilly announce their ...

An international research team reveals new molecular mechanisms associated with pathogenic mutations in the protein ...

Eli Lilly (LLY) stock is in focus as Nimbus Therapeutics expands its research deal to develop an oral obesity drug in a deal ...

Discover how AI is revolutionizing RNA drug development in a new article published in Engineering. Learn about the potential ...

In the realm of modern medicine, RNA-based therapies have emerged as a promising avenue, with significant advancements in metabolic diseases, oncology, and preventive vaccines. A recent article ...

Drug discovery has long relied on two key strategies: target-based and phenotypic screening. Recombinant technologies and genomics opened the door to modern target-based drug discovery (TBDD), ...

Eli Lilly will partner with Nimbus Therapeutics to develop an oral treatment for obesity and other metabolic diseases, through a multi-year research collaboration and exclusive worldwide license ...

MIT researchers are now turning the prolific Boltz series of models into a software company that promotes open science for AI-guided therapeutics.

The Singapore-based AI clinical trial engine powering Asia’s—especially China’s—rapid rise in the biotech industry. Deep ...